Neurotrophic Keratitis Market Regional Analysis:
North American Market Insights
The neurotrophic keratitis market in North America is projected to be the largest with revenue share of 32% by the end of 2035. The market for neurotrophic keratitis is growing in North America because to the dominance of large players in the region and the increasing number of new product launches. Moreover, congenital conditions, herpes simplex infections, chemical or thermal burns, diabetes, cranial nerve injury, and chronic conditions of the ocular surface are common causes of neurotrophic keratopathy. In 2021, 29.7 million Americans of all ages (8.9% of the US population) had been diagnosed with diabetes, according to the CDC, and by the time they reach their fifth decade of life, about 12% of Americans had tested positive for HSV-2. Effective therapies are in higher need as the prevalence of these causal variables increases and incidences of neurotrophic keratitis rise.
APAC Market Insights
The Asia Pacific neurotrophic keratitis market is estimated to witness substantial demand during the forecast period. The focus on early detection and cutting-edge treatment options for eye illnesses is growing in the region's healthcare system. The market is growing as a result of factors like increased healthcare spending, bettering medical infrastructure, and a rise in R&D activity. The need for healthcare is also growing since those over 65 are quickly making up a greater share of the population in Southeast Asia (especially in the more populous countries of Indonesia, Vietnam, Thailand, and the Philippines), China, and India. The percentage of adults in ASEAN countries who are 60 years of age or older was 9.8% in 2017, and according to WHO estimates, that number is projected to increase to 13.7% in 2030 and 20.3% by 2050.
